You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is Wrong statement about SGLT (sodium-glucose linked transpoer) and explain in detail?
SGLT2 inhibitors reduce hospitalisation for hea failure as demonstrated by multiple cardiovascular outcome trials of various SGLT2 inhibitors. They produce glycosuria and weight loss. SGLT2 is a high capacity low affinity transpoer in contrast to SGLT1. In kidneys, SGLT2 is present in the proximal pa of the tubules while SGLT1 is present more distally. The low amount of glucose remaining after transpo by the SGLT2 is conserved by SGLT1 located distally as it has high affinity for glucose compared to SGLT2, produce viual absence of glucose in urine. Reference: Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotranspoer inhibitors: effects on renal and intestinal glucose transpo: from bench to bedside. Diabetes care. 2019 Dec 1;38(12):2344-53.